Related Experiment Video
Updated: May 12, 2026
High-throughput Quantitative Real-time RT-PCR Assay for Determining Expression Profiles of Types I and III Interferon Subtypes
Published on: March 24, 2015
Hope and fear for interferon: the receptor-centric outlook on the future of interferon therapy
1Department of Animal Biology and Mari Lowe Center for Comparative Oncology, School of Veterinary Medicine, University of Pennsylvania , Philadelphia, PA 19104-4539, USA. syfuchs@vet.upenn.edu
Abstract:
After several decades of intense clinical research, the great promise of Type I interferons (IFN1) as the anticancer wonder drugs that could cure or, at the very least, curb the progression of various oncological diseases has regrettably failed to deliver. Severe side effects and low efficacy of IFN1-based pharmaceutics greatly limited use of these drugs and further reduced the enthusiasm of clinical oncologists for future optimization of IFN1-based therapeutic modalities. Incredibly, extensive clinical studies to assess the efficacy of IFN1 alone or in combination with other anticancer drugs have not been paralleled by an equal scope in defining the determinants that confer cell sensitivity or refractoriness to IFN1. Given that all effects of IFN1 on malignant and benign cells alike are mediated by its receptor, the mechanisms regulating these receptor cell surface levels should play a paramount role in shaping the magnitude and duration of IFN1-elicited effects. These mechanisms and their role in controlling IFN1 responses, as well as an ability of a growing tumor to commandeer these events, are the focus of our review. We postulate that activation of numerous signaling pathways leading to elimination of IFN1 receptor occurs in cancer cells and benign cells that contribute to tumor tissue. We further hypothesize that activation of these eliminative pathways enables the escape from IFN1-driven suppression of tumorigenesis and elicits the primary refractoriness of tumor to the pharmaceutical IFN1.
Insights
Type I interferons (IFN1) show limited efficacy in cancer treatment due to severe side effects. Tumor cells may evade IFN1 therapy by eliminating IFN1 receptors, causing treatment refractoriness.
Area of Science:
- Oncology
- Immunology
- Molecular Biology
Background:
- Type I interferons (IFN1) were once promising anticancer agents but have shown limited clinical success.
- Severe side effects and low efficacy have hindered the therapeutic application of IFN1-based drugs.
- Understanding the mechanisms of IFN1 resistance is crucial for improving cancer therapy.
Purpose of the Study:
- To review the mechanisms that regulate Type I interferon receptor (IFN1R) cell surface levels.
- To explore how tumors exploit these mechanisms to develop refractoriness to IFN1 therapy.
- To identify determinants of cell sensitivity and refractoriness to IFN1.
Main Methods:
- Review of existing clinical and preclinical studies on Type I interferons and cancer.
- Analysis of signaling pathways involved in IFN1 receptor regulation.
- Examination of tumor cell strategies for evading IFN1-mediated responses.
Main Results:
- IFN1 therapy has largely failed to meet expectations for cancer treatment due to efficacy and side effect limitations.
- Mechanisms controlling IFN1 receptor cell surface levels are critical for modulating IFN1 response magnitude and duration.
- Cancer cells and associated benign cells activate pathways that eliminate IFN1 receptors, leading to primary refractoriness.
Conclusions:
- Tumor refractoriness to IFN1 is linked to the activation of signaling pathways that eliminate the IFN1 receptor.
- Understanding and targeting these receptor-regulating mechanisms could overcome IFN1 resistance in cancer.
- Further research into IFN1 receptor regulation is essential for optimizing IFN1-based cancer therapeutics.
Related Concept Videos
01:30Inhibitors of Viral Protein Synthesis
01:23RNA Interference
This process occurs naturally in cells, often through the activity of genomically-encoded microRNAs. Researchers can take advantage of this mechanism by introducing synthetic RNAs to deactivate specific genes for research or therapeutic purposes. For example, RNAi could be used...
01:23RNA Interference
This process occurs naturally in cells, often through the activity of genomically-encoded microRNAs. Researchers can take advantage of this mechanism by introducing synthetic RNAs to deactivate specific genes for research or therapeutic purposes. For example, RNAi could be used...
02:56Treatment Resistent Cancers
01:29Microorganisms in Medicine and Therapeutics
02:56Treatment Resistant Cancers